[2024/11/15] Gene and Cell Therapy- weekly digest from PackGene

Nov 15, 2024

Featured

Nov 13 US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder read more »
Nov 13 One-time gene therapy reverses liver disease MASH in mouse models read more »
Nov 11 Autolus secures FDA approval for CAR-T cell therapy use in ALL read more »
News
Nov 14 Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy read more »
Nov 13 Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies read more »
Nov 13 Ireland's SSPC and NIBRT Team to Take on Biopharma Bottlenecks read more »
Nov 13 Biden officials warn of threat to U.S. children if anti-vaccine views prevail read more »
Nov 13 Inflammation-reducing molecule provides a new target for treating atherosclerosis read more »
Nov 07 Sarepta scraps a Duchenne drug as gene therapy sales rise read more »
Articles
Nov 13 Directed evolution of engineered virus-like particles with improved production and transduction efficiencies read more »
Nov 12 Multimodal scanning of genetic variants with base and prime editing read more »
Nov 12 A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases | Nature Communications read more »
Nov 11 The disparate burden of infectious diseases | Gene Therapy read more »
Nov 11 Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies read more »
Nov 08 Binding-driven forward tearing protospacer activated CRISPR-Cas12a system and applications for microRNA detection read more »
Nov 08 Neuroimaging Applications for the Delivery and Monitoring of Gene Therapy for Central Nervous System Diseases read more »
Nov 07 Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles read more »

PackGene’s Newsletter

Receive the latest news and insights to your inbox.

Subscribe Now
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

AAV Packaging Services

We have developed a series of proprietary technologies that greatly improve AAV production outcomes including titer, purity, potency, and consistency.

READ MORE

Off-the-Shelf AAV Products

We offer a library of carefully designed and pre-stocked AAV vectors for a wide variety of experimental needs.

READ MORE